Inclusion Criteria : 
  1.  Hospitalized patient ≥ 18 years old or considered an adult in accordance with the age of majority in the participant's country of residence at the time of treatment with ceftazidime - avibactam. 
  2.  Patient received ≥ 1 dose of ceftazidime - avibactam in routine practice at participating site since 01 January , 2018 onwards or since the date of launch in the country if it is after 01 January , 2018. 
  3.  Patient underwent microbiologic sampling ≤ 5 days before the initiation of ceftazidime - avibactam ( irrespective of results and actual bacteriological identification ) . 
  4.  Patient has all required essential data elements which include : 
       1.  Start and stop dates of ceftazidime - avibactam , 
       2.  Start and stop dates of prior antibiotic therapy used for the index infection , 
       3.  Type of combined antibiotic therapy ( if applicable ) and start and stop dates of any antibiotic combined with ceftazidime - avibactam. 
  5.  Evidence of a personally signed and dated informed consent document indicating that the patient ( or a legally acceptable representative ) has been informed of all pertinent aspects of the study where required by local regulations. 
Exclusion Criteria : 
Patients must not meet any of the following exclusion criteria to be eligible : 
  1.  The patient is enrolled in any clinical trial of an investigational product.  Patients who are enrolled in non - interventional studies ( NISs ) ( e. g.  registries ) are eligible for inclusion. 
  2.  The patient has received ceftazidime - avibactam in a compassionate care program setting. 
  3.  The patient was exposed to ceftazidime - avibactam before use for the index infection.